Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program
PM360
SEPTEMBER 21, 2023
They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.
Let's personalize your content